114 followers
RT @FrontImmunol: New Research: CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Car…
RT @FrontImmunol: New Research: CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Car…
New Research: CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Carcinoma: Background The emergence of immune checkpoint inhibitors (ICIs) marks the beginning of a new era of immunotherapy… https://t.co